RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+15.7%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$973M
AUM Growth
+$326M
(+50%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
22.62%
Top 10 Holdings %
Top 10 Hldgs %
66.39%
Holding
36
New
7
Increased
5
Reduced
7
Closed
2
Top Buys
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$68.6M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$61.6M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
$52.2M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
$25.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
$18.8M |
Top Sells
| 1 |
Acadia Pharmaceuticals
ACAD
|
$22.4M |
| 2 |
TherapeuticsMD
TXMD
|
$11.5M |
| 3 |
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
|
$8.32M |
| 4 |
ENZ
Enzo Biochem, Inc.
ENZ
|
$6.62M |
| 5 |
Novavax
NVAX
|
$3.96M |
Sector Composition
| 1 | Healthcare | 84.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OCRX
26
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $5.57M | 0.4% |
527,797
-133,899
| -20% | -$1.41M |
|
27
MacroGenics
MGNX
$126M
| $5.55M | 0.4% |
199,398
| – | – |
|
|
ALIM
28
DELISTED
Alimera Sciences, Inc.
ALIM
| $5.26M | 0.38% |
+44,444
| New | +$5.26M |
|
29
MEI Pharma
MEIP
$139M
| $4.55M | 0.33% |
20,417
| – | – |
|
|
ATHE
30
Alterity Therapeutics
ATHE
| – | – |
0
| – | – |
|
31
Fortress Biotech
FBIO
$110M
| – | – |
0
| – | – |
|
32
Gilead Sciences
GILD
$143B
| – | – |
0
| – | – |
|
33
Rockwell Medical
RMTI
$55.8M
| – | – |
0
| – | – |
|
|
ENZ
34
DELISTED
Enzo Biochem, Inc.
ENZ
| – | – |
-2,268,653
| Closed | -$6.62M |
|
|
LUMO
35
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| – | – |
0
| – | – |
|
|
CHTP
36
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
| – | – |
-666,667
| Closed | -$2.96M |
|